Of 19 patients who had stents placed at sites of previous PTA, primary (unassisted) patency at six months increased from 14% for PTA without stenting to 72% after PTA with stenting; mean primary patency increased from 2.5 to 10.6 months.
Sreenarasimhaiah et al [6] obtained similar encouraging results in this issue of Kidney International. They studied the clinical course of 34 patients after placement of SMART stents as treatment of venous anastomotic lesions in thrombosed AVGs unresponsive to PTA. Criteria for inclusion in the study included PTA of the same lesion within the previous three months, lumen collapse immediately post-PTA because of elastic recoil, or significant residual stenosis post-PTA. Treatment with clopidogrel post-procedure was an additional feature of the study. The AVGs averaged of 17.9 months of age, and 84% had one or more endovascular or surgical procedures before this thrombosis. The results of this study are remarkable: primary patency after stent placement was 63% and 36% at six months and one year, respectively, and secondary (assisted) patency was 88% and 86% at six months and one year, respectively.
In attempting to explain this study's encouraging results, a potential role of clopidogrel should be considered. In AVGs, previous studies with bare-metal stents have not employed currently available antiplatelet agents. It should be noted that antiplatlet therapy has become the standard of care after intracoronary stent implantation. Regarding AVGs, Sreedhara et al demonstrated a significant reduction in the number of thromboses in newly created AVGs that were treated with dipyridamole compared with placebo, but there was no benefit in previously thrombosed AVGs [8] . However, more recent experience with antiplatelet agents has not been encouraging. A randomized controlled trial evaluated the role of clopidogrel plus aspirin in preventing AVG thrombosis [9] . The study was discontinued early because of a marked increase in bleeding episodes in the treatment group. The study showed no difference in thrombosis rates between the treatment and placebo groups. Thus, it is unclear whether clopidogrel played a significant role in the favorable outcome of Sreenarasimhaiah et al's study [6] . K/DOQI does not currently recommend use of antiplatelet agents or anticoagulation to prevent AVG thrombosis.
The study by Sreenarasimhaiah et al indicates that despite improved patency, neointimal hyperplasia continues unabated [6] . For example, in the 21 of 34 patients that required repeat procedures, 81% (17/21) had lesions outside the stent. Moreover, in 43% of repeat procedures, the original stented lesion was not implicated as the cause of AVG dysfunction. Thus, stenting may delay abandonment of the AVG, but does not provide the more desirable (but not yet attainable) definitive prevention or treatment of neointimal hyperplasia. Nevertheless, this result, if confirmed, is noteworthy because any treatment that prolongs access function delays the day when the patient runs out of access sites.
In conclusion, we must find better ways to prevent and treat neointimal hyperplasia. Novel strategies to prevent AV graft stenosis by using pharmacologic and other therapies are underway (NIH DAC Study and others). Nevertheless, until truly effective therapies are found, our options are limited. In light of this new data with nitinol stents, we must push for randomized controlled trials that will test their efficacy as an adjunct to PTA. If future studies demonstrate that stent placement prolongs access survival and reduces intervention, the added costs of stents may be offset by decreased access morbidity and reduced total access-related costs. Drug-eluting stents are very expensive but may be even more effective. PTA combined with stent deployment may be the combination that opens a new era of improved therapy of recurrent stenosis.
